Catalyst Pharmaceuticals (CPRX) Tops Q4 EPS by 37c, Offers Guidance
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
Financial Fact:
General and administrative: 1.42M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
General and administrative: 1.42M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 EPS of $0.68, $0.37 better than the analyst estimate of $0.31. Revenue for the quarter came in at $152.6 million versus the consensus estimate of $141.49 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2026 revenue of $615-645 million, versus the consensus of $615.6 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
- BofA says CTA Treasury shorts stable, euro short-cover risk rises
- ICICI Securities Resumes Dalmia Bharat Ltd (DALBHARA:IN) at Add (2)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
